CFOO · XBRL financial data
China Foods Holdings financial statements, every quarter
The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (CFOO's year ends in late December)
| In thousands of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 24 | — | — | — | 0 | — | — | — | — | — |
| Revenue from contracts with customers | 5 | 134* | 24 | 4 | 22 | 183* | 0 | 142 | 97 | 89* | 0 | 0 |
| Cost of revenue | 2 | 82* | 6 | 1 | 21 | 151* | 0 | 127 | 88 | 83* | 0 | 0* |
| Gross profit | 4 | 52* | 18 | 2 | 1 | 32* | 0 | 16 | 9 | 6* | 0 | 0 |
| General and administrative | 117 | 101* | 90 | 111 | 111 | 190* | 99 | 113 | 88 | 124* | 62 | 64 |
| Total operating expenses | 117 | 101* | 95 | 111 | 112 | 191* | 104 | 113 | 88 | 124* | 62 | 64 |
| Operating income (loss) | (114) | (49)* | (78) | (109) | (111) | (159)* | (104) | (97) | (79) | (119)* | (62) | (64) |
| Other income (expense) | — | year only | 0 | 0 | 0 | 0* | 0 | 0 | 0* | 0* | — | — |
| Income tax expense (benefit) | — | — | (16) | (0) | 17 | 0* | — | 0 | — | — | — | 0 |
| Net income (loss) | (114) | (49)* | (62) | (108) | (127) | (158)* | (104) | (97) | (79) | (119)* | (62) | (64) |
| Earnings per share, basic USD per share | (0.01) | 0.00* | 0.00 | (0.01) | (0.01) | (0.01)* | (0.01) | 0.00 | 0.00 | (0.01)* | 0.00 | 0.00 |
| Earnings per share, diluted USD per share | (0.01) | 0.00* | 0.00 | (0.01) | (0.01) | (0.01)* | (0.01) | 0.00 | 0.00 | (0.01)* | 0.00 | 0.00 |
| Weighted average shares, basic thousands of shares | 20,252 | 20,252* | 20,252 | 20,252 | 20,252 | 20,252* | 20,252 | 20,252 | 20,252 | 20,252* | 20,252 | 20,252 |
| Weighted average shares, diluted thousands of shares | 20,252 | 20,252* | 20,252 | 20,252 | 20,252 | 20,252* | 20,252 | 20,252 | 20,252 | 20,252* | 20,252 | 20,252 |
Balance sheet
CSVFiscal quarters (CFOO's year ends in late December)
| In thousands of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | 157 | 175 | 123 | 75 | 66 | 39 | 24 | 64 | 77 | 10 | 10 | 16 |
| Accounts receivable | 5 | 39 | — | — | — | — | — | — | — | — | — | — |
| Inventory | 119 | 48 | 59 | 59 | 71 | 55 | 79 | 98 | 46 | 39 | 40 | 40 |
| Prepaid and other current assets | — | 67 | 68 | 61 | 77 | 303 | 318 | 146 | 122 | 108 | 109 | 112 |
| Total current assets | 344 | 350 | 257 | 246 | 251 | 399 | 427 | 318 | 251 | 163 | 164 | 174 |
| Property and equipment, net | 18 | 13 | 13 | 17 | 17 | 34 | 33 | 31 | 29 | 28 | 26 | 25 |
| Right-of-use asset | 34 | — | — | — | — | — | — | — | — | 20 | 18 | 15 |
| Total assets | 398 | 365 | 272 | 264 | 270 | 435 | 462 | 351 | 282 | 213 | 210 | 216 |
| Accounts payable | 1 | — | — | — | 34 | — | — | — | 2 | — | — | — |
| Total current liabilities | 740 | 756 | 727 | 828 | 966 | 1,286 | 1,417 | 1,408 | 1,430 | 1,481 | 1,543 | 1,626 |
| Lease liability, non-current | — | — | — | — | — | — | — | — | — | 10 | 7 | 4 |
| Total liabilities | — | — | — | — | — | 1,286 | — | — | — | 1,490 | 1,550 | 1,630 |
| Accumulated deficit | (1,627) | (1,676) | (1,738) | (1,846) | (1,973) | (2,132) | (2,235) | (2,332) | (2,412) | (2,530) | (2,592) | (2,656) |
| Total stockholders' equity | (342) | (391) | (455) | (564) | (696) | (851) | (955) | (1,057) | (1,149) | (1,277) | (1,340) | (1,414) |
| Total liabilities and equity | 398 | 365 | 272 | 264 | 270 | 435 | 462 | 351 | 282 | 213 | 210 | 216 |
| Common shares outstanding (cover page) thousands of shares | 20,252 | 20,252 | 20,252 | 20,252 | 20,252 | 20,252 | 20,252 | 20,252 | 20,252 | 20,252 | 20,252 | 20,252 |
Cash flows
CSVFiscal quarters (CFOO's year ends in late December)
| In thousands of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | (114) | (49)* | (62) | (108) | (127) | (158)* | (104) | (97) | (79) | (119)* | (62) | (64) |
| Net cash from operating activities | (81)* | (62)* | (49) | (67)* | (86)* | (152)* | (101) | (86)* | (69)* | (133)* | (56) | (94)* |
| Purchases of property and equipment | — | 0* | — | — | 0* | 19* | — | — | — | — | — | — |
| Net cash from investing activities | — | (0)* | — | — | 0* | (19)* | — | — | — | — | — | — |
| Net cash from financing activities | (5)* | 80* | (1) | 24* | 81* | 141* | 86 | 131* | 95* | 77* | 57 | 111* |
| Net change in cash | (86)* | 17* | (52) | (47)* | (10)* | (26)* | (16) | 40* | 13* | (67)* | (0) | 6* |
Compare with peers
SIC 2833 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2833 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| China Foods Holdings | 16 | 0 | (94)* | 20.3M | 0.2 quarters | 10-QJun 30, 2026 |
| Mosaic ImmunoEngineering | 0 | not reported | (0)* | 7.2M | 0.6 quarters | 10-QJun 30, 2026 |
| Hepion Pharmaceuticals | 1,629 | not reported | (1,394)* | 90.2M | 1.2 quarters | 10-QJun 30, 2026 |
| Twinlab Consolidated Holdings | 13 | not reported | (907)* | 259.1M | 0.0 quarters | 10-KDec 31, 2024 |
| Regen BioPharma | 0.2 | 59 | (24)* | 1.7B | 0.0 quarters | 10-QJun 30, 2026 |
| Nutra Pharma | not reported | 34 | (251)* | 7.2B | 0.1 quarters | 10-QJun 30, 2026 |
| Evofem Biosciences | 285 | 2,633 | (3,140)* | 132.5M | 0.1 quarters | 10-QJun 30, 2026 |
| International Stem Cell | 1,089 | 2,675 | 167* | 8.0M | — | 10-QJun 30, 2026 |
| Emmaus Life Sciences | 2,808 | 6,318 | 1,693* | 70.2M | — | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.